Osimertinib, an FDA-approved lung cancer drug, slashes the risk of death for certain patients by 51%, according to new trial results.

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs². It exhibits a nine-fold greater affinity for select EGFR-sensitizing and T790M-resistance mutations than to wild-type EGFR¹.

(1) . https://bing.com/search?q=osimertinib+mechanism+of+action. (2) DRUG NAME: Osimertinib - BC Cancer. http://www.bccancer.bc.ca/drug-database-site/Drug Index/Osimertinib_monograph.pdf. (3) Mechanism of Action – TAGRISSO® (osimertinib). https://www.tagrissohcp.com/moa.html. (4) Osimertinib: Uses, Interactions, Mechanism of Action | DrugBank Online. https://go.drugbank.com/drugs/DB09330. (5) Mechanisms of osimertinib resistance and emerging treatment … - PubMed. https://pubmed.ncbi.nlm.nih.gov/32693293/.